# Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

> **NCT05746611** · PHASE4 · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 7500 (actual)

## Conditions studied

- Latent Tuberculosis Infection

## Interventions

- **BIOLOGICAL:** Recombinant Mycobacterium tuberculosis fusion protein for injection
- **BIOLOGICAL:** TB-PPD was injected

## Key facts

- **NCT ID:** NCT05746611
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-17
- **Primary completion:** 2024-05-13
- **Final completion:** 2024-05-13
- **Target enrollment:** 7500 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05746611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05746611, "Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05746611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*